康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌患者免疫功能和肿瘤标志物的影响

Effects of kanglaite intravenous injection combined with cisplatin perfusion on immune function and tumor markers in patients with advanced NSCLC

目的:探究康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌(NSCLC)患者免疫功能和肿瘤标志物的影响。方法:选取于接受治疗的Ⅲb-Ⅳ期NSCLC患者124例为研究对象,入院编号后经单双号法分为顺铂组(单号,62例,给予顺铂胸腔灌注方案化疗)和康莱特组(双号,62例,给予康莱特联合顺铂胸腔灌注方案)。治疗4个疗程后,比较两组客观缓解率(ORR)和疾病控制率(DCR)、治疗前后甲胎蛋白(AFP)、癌胚抗原(CEA)和癌抗原125(CA125)及免疫球蛋白(IgG、IgA、IgM)和T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平变化。记录药物不良反应发生情况。结果:化疗4个疗程后,两组ORR比较无统计学差异(P>0.05),康莱特组DCR显著高于顺铂组(P<0.05);两组AFP、CEA、CA125水平降低,且康莱特组低于顺铂组(均P<0.05);康莱特组IgG、IgA、IgM水平降低,顺铂组IgA水平降低,且康莱特组低于顺铂组(均P<0.05);康莱特组CD3^(+)、CD4^(+)/CD8^(+)水平降低,CD4^(+)水平显著升高,顺铂组CD4^(+)/CD8^(+)水平升高,且康莱特组CD3^(+)、CD4^(+)/CD8^(+)水平低于顺铂组,CD4^(+)水平高于顺铂组(均P<0.05);康莱特组恶心呕吐、泌尿系统损伤发生率低于顺铂组(均P<0.05)。结论:康莱特静脉注射联合顺铂灌注化疗可抑制晚期NSCLC患者肿瘤生长,降低肿瘤标志物水平,提高机体免疫功能,降低化疗不良反应,安全性较好。

Objective:To investigate the effect of kanglaite intravenous injection combined with cisplatin perfusion on immune function and tumor markers in patients with advanced non-small cell lung cancer(NSCLC).Methods:A total of 124 patients with stageⅢb-ⅣNSCLC who received treatment were selected as the study subjects.After admission,they were divided into cisplatin group(odd number,62 cases,treated with cisplatin intrapleural perfusion chemotherapy)and kanglaite group(even number,62 cases,treated with kanglaite combined with cisplatin intrapleural perfusion chemotherapy)by odd and even number method.After four courses of treatment,the objective response rate(ORR)and disease control rate(DC),alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA)and cancer antigen 125(CA125),immune function indexes(IgG,IgA,IgM,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+))before and after treatment were compared between the two groups.The occurrence of adverse drug reactions was recorded.Results:After 4 courses of chemotherapy,there was no significant difference in ORR between the two groups(P>0.05),while the DCR in the kanglaite group was significantly higher than that in the cisplatin group(P<0.05);the levels of AFP,CEA and CA125 in the two groups were decreased,and those in the kanglaite group were lower than those in the cisplatin group(all P<0.05);the levels of IgG,IgA and IgM in the kanglaite group were decreased,and the level of IgA in the cisplatin group was decreased,and the level of IgA in the kanglaite group was lower than that in the cisplatin group(all P<0.05);the levels of CD3^(+)and CD4^(+)/CD8^(+)in kanglaite group were declined,while the level of CD4^(+)was significantly risen,and the level of CD4^(+)/CD8^(+)was significantly elevated,and the levels of CD3^(+)and CD4^(+)/CD8^(+)in kanglaite group were significantly lower and the level of CD4^(+)was higher compared to cisplatin group(all P<0.05);the incidence of nausea and vomiting and urinary system injury in the kanglaite group was lower than that in the cisplatin group(all P<0.05).Conclusion:Kanglaite intravenous injection combined with cisplatin chemotherapy can inhibit tumor growth in patients with advanced NSCLC,reduce the levels of tumor markers,improve the immune function of the body,and reduce the adverse reactions of chemotherapy,with good safety.